We recently hired Michael Austin, Chief Experience Officer (CXO), as a new central role within the CDM network. The CXO will inspire, build, and activate customer experience strategies to deliver differentiated brand experiences that drive customer loyalty and advocacy. This new practice is a connector between our strategy, creative, technology, data, and analytics teams, with the remit of creating customer engagement in the moments that matter and develop personalized, cross-channel solutions with the individual in mind. Amplifying that capability is the hire of our own head of Customer Engagement at CDMP, Peter DeLorenzo. Peter's background in data-heavy CRM, digital, and omnichannel is exactly what our clients need to maximize their spend and create meaningful, lasting, and impactful customer interactions at every touch point. Another area of growth for us is in social. We are finding more and more clients embracing and activating Digital Opinion Leaders, and our social team is masterful at identifying the most appropriate, onboarding and training them, and co-creating the most relevant and authentic content with them.
Abbott Point of Care – i-STAT Alinity TBI Plasma Test BioMarin – gene therapy BioMarin – Hemophilia BioMarin - PKU Bristol Bristol Myers Squibb – myeloid SK Life Science – Xcopri Sun Pharmaceuticals – Ilumya Teva – Bendeka Teva – Granix Teva – Truxima Sage/Biogen – MDD Emerging Biotechnology - Corporate Identity/Pipeline Development
2021 Growth from Existing Clients
2021 Growth from New Clients
Trends and Challenges
Diversity and inclusionTalent acquisition/retentionManaging growthPayer-related challengesPricing-related issuesKeeping up with pace of innovationReplenishing new-business pipelineProcurement-related issuesNetwork relationships/agency consolidationShrinking pharma budgetsFurther diversification of servicesRegulatory concernsPandemic-related disruptionsNeed for private equity/capital infusion
Healthcare Marketing Trends
More personalization of communicationsNeed to create more/better content/experiencesHeightened focus on payersIncreased concern over drug pricingIndustry consolidationScrutiny around social mediaImpact of empowered patients/consumersIntensified focus on analytics/ROI/measurementDecreased impact of sales forcesRegulatory changesPrograms that go “beyond the pill”Evolution of EHRsEmphasis on specialty drugs/high-science categoriesAdopting a data-science cultureMore digital experimentationWorking from homeOngoing fallout from pandemicOngoing fallout from societal unrest